Vascular calcification in patients with chronic kidney disease

Therapeutic Apheresis and Dialysis

Volumn 15, Issue 6, 2011, Pages 513-521

  Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Arterial calcification; Hemodialysis; Hyperphosphatemia; Non calcium phosphate binder; Review; Vitamin D

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; ETIDRONIC ACID; FIBROBLAST GROWTH FACTOR 23; LANTHANUM; PHOSPHORUS; SEVELAMER;

ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CALCIUM METABOLISM; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; HUMAN; HYPERPHOSPHATEMIA; NONHUMAN; PATHOPHYSIOLOGY; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SMOOTH MUSCLE FIBER;

ANIMALS; CALCINOSIS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DRUG DESIGN; HUMANS; KIDNEY DISEASES; RISK FACTORS; VASCULAR DISEASES;

EID: 82155162466     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2011.00979.x     Document Type: Review

References (90)

1. Moe SM, Drueke T, Lameire N, Eknoyan G. Chronic kidney disease-mineral- bone disorder: a new paradigm. Adv Chronic Kidney Dis 2007;14:3-12.
2. Goldsmith D, Covic A, Sambrook P, Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 1997;77:37-43.
3. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008;19:213-6.
4. Shroff RC, Shanahan CM. The vascular biology of calcification. Semin Dial 2007;20:103-9.
5. Chertow GM, Raggi P, Chasan-Taber S etal. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19:1489-96.
6. Raggi P, Bellasi A, Ferramosca E, Islam T, Muntner P, Block GA. Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients. Kidney Int 2007;71:802-7.
7. Nitta K, Akiba T, Uchida K etal. Left ventricular hypertrophy is associated with arterial stiffness and vascular calcification in hemodialysis patients. Hypertens Res 2004;27:47-52.
8. Nitta K, Akiba T, Suzuki K etal. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 2004;44:680-8.
9. Raggi P, Chertow GM, Torres PU etal. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011;26:1327-39 (doi:10.1093/ndt/gfg725).
10. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793-808.
11. Elliott RJ, McGrath LT. Calcification of the human thoratic aorta during age. Calcif Tissue Int 1994;54:268-73.
12. Atkinson J. Age-related medial elastocalcinosis in arteries: mechanisms, animal models, and physiological consequences. J Appl Physiol 2008;105:1643-51.
13. Shanahan C, Cary N, Salisbury J, Proudfoot D, Weissberg P, Edmonds M. Medial localization of mineralization-regulating proteins in association with Monckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation 1999;100:2168-76.
14. Shioi A, Taniwaki H, Jono S etal. Monckeberg's medial sclerosis and inorganic phosphate in uremia. Am J Kidney Dis 2001;38:S47-9.
15. Wexler L, Brundage B, Crouse J etal. Coronary artery calcification: pathophysiology, epidemiology, imaging methods, and clinical implications. A statement for health professionals from the American Heart Association. Circulation 1996;94:1175-92.
16. London G, Marchais S, Guerin A, Metivier F, Adda H. Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant 2002;17:1713-24.
17. Dhore CR, Cleutjens JP, Lutgens E etal. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001;21:1998-2003.
18. Chillon JM, Mozar A, Six I etal. Pathophysiological mechanisms and consequences of cardiovascular calcifications: role of uremic toxicity. Ann Pharm Fr 2009;67:234-40.
19. Shroff RC, McNair R, Figg N etal. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008;118:1748-57.
20. Chen NX, Duan D, O'Neill KD etal. The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells. Kidney Int 2006;70:1046-53.
21. Speer MY, Yang HY, Brabb T etal. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ Res 2009;104:733-41.
22. Cannata-Andia JB, Rodriguez-Garcia M, Carrillo-Lopez N, Naves-Diaz M, Diaz-Lopez B. Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol 2006;17(12 Suppl 3):S267-73.
23. Raggi P, Boulay A, Chasan-Taber S etal. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695-701.
24. Kanbay M, Goldsmith D, Akcay A, Covic A. Phosphate: the silent stealthy cardiorenal culprit in all stages of chronic kidney disease: a systematic review. Blood Purif 2009;27:220-30.
25. Kestenbaum B, Sampson JN, Rudser KD etal. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-8.
26. Yang H, Curinga G, Giachelli C. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 2004;66:2293-9.
27. Reynolds JL, Joannides AJ, Skepper JN etal. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 2004;15:2857-67.
28. Jono S, McKee M, Murry C etal. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000;87:E10-17.
29. El-Abbadi MM, Pai AS, Leaf EM etal. Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int 2009;75:1297-307.
30. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-201.
31. Levin A, Bakris G, Molitch M etal. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-8.
32. Holick M. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
33. Barreto DV, Barreto FC, Liabeuf S etal. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1128-35.
34. Li Y, Kong J, Wei M, Chen Z, Liu S, Cao L. 1, 25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110:229-38.
35. Henley C, Colloton M, Cattley RC etal. 1, 25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 2005;20:1370-7.
36. Mathew S, Lund R, Chaudhary L, Geurs T, Hruska K. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 2008;19:1509-19.
37. Shimada T, Kakitani M, Yamazaki Y etal. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004;113:561-8.
38. Shimada T, Hasegawa H, Yamazaki Y etal. FGF23 is a potent regulator of the vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429-35.
39. Segawa H, Kawakami E, Kaneko I etal. Effect of hydrolysis-resistant FGF23-R179Q on dietary phosphate regulation of the renal type II Na/Pi transporter. Pflugers Arch 2003;446:585-92.
40. Kuro-o M, Matsumura Y, Aizawa H etal. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51.
41. Tsujikawa H, Kurotaki Y, Fujimori T etal. Klotho, a gene related to a syndrome resembling human premature ageing, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003;17:2393-403.
42. Razzaque MS, Sitara D, Taguchi T etal. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin d-mediated process. FASEB J 2006;20:720-2.
43. Nakatani T, Sarraj B, Ohnishi M etal. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23)-mediated regulation of systemic phosphate homeostasis. FASEB J 2009;23:433-41.
44. Kurosu H, Ogawa Y, Miyoshi M etal. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006;281:6120-3.
45. Mohammadi M, Olsen SK, Ibrahimi OA. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 2005;16:107-37.
46. Krajisnik T, Björklund P, Marsell R etal. Fibroblast growth factor-23 regulates parathyroid hormone and 1-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007;195:125-31.
47. Kawata T, Imanishi Y, Kobayashi K etal. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007;18:2683-8.
48. Sitara D, Razzaque MS, St-Armaud R etal. Geetic ablation of vitamin D activation pathway reverses biochemical and skeletal anormalies in Fgf-23 null animals. Am J Pathol 2006;169:2161-70.
49. Aoki A, Kojima F, Uchida K, Tanaka Y, Nitta K. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic hemodialysis patients. Geriatr Geronntol Int 2009;9:246-52.
50. Narcovitz PA, Tran HH, Franklin BA etal. Usefulness of bone mineral density to predict significant coronary artery disease. Am J Cardiol 2005;96:1059-63.
51. Lanske B, Razzaque MS. Mineral metabolism and aging: the fibroblast growth factor 23 enigma. Curr Opin Nephrol Hypertens 2007;16:311-8.
52. Ketteler M, Vermeer C, Wanner C, Westenfeld R, Jahnen-Dechent W, Floege J. Novel insights into uremic vascular calcification: role of matrix Gla protein and α-2-Heremans Schmid glycoprotein/fetuin. Blood Purif 2002;20:473-6.
53. Ketteler M, Wanner C, Metzger T etal. Deficiencies of calcium-regulatory proteins in dialysis patients: a novel concept of cardiovascular calcification in uremia. Kidney Int 2003;Suppl 84:S84-7.
54. Schafer C, Heiss A, Schwarz A etal. The serum protein α2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003;112:357-66.
55. Reynolds JL. Multifunctional roles for serum protein fetuin-A in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005;16:2920-30.
56. Price P, Williamson M. Primary structure of bovine matrix Gla protein, a new vitamin K-dependent bone protein. J Biol Chem 1985;260:14971-5.
57. Cancela L, Hsieh CL, Francke U, Price PA. Molecular structure, chromosome assignment, and promoter organization of the human matrix Gla protein gene. J Biol Chem 1990;265:15040-8.
58. Luo G, Ducy P, McKee M etal. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997;386:78-81.
59. Bostrom K, Tsao D, Shen S, Wang Y, Demer L. Matrix GLA protein modulates differentiation induced by bone morphogenetic protein-2 in C3H10T1/2 cells. J Biol Chem 2001;276:14044-52.
60. Parker B, Ix J, Cranenburg E, Vermeer C, Whooley M, Schurgers L. Association of kidney function and uncarboxylated matrix Gla protein: data from the Heart and Soul Study. Nephrol Dial Transplant 2009;24:2095-101.
61. Collin-osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004;95:1046-57.
62. Morena M, Dupuy AM, Jaussent I etal. A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. Nephrol Dial Transplant 2009;24:3389-97.
63. Nitta K, Akiba T, Uchida K etal. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19:1886-9.
64. -/- mice. Arterioscler Thromb Vasc Biol 2006;26:2117-24.
65. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 2003;88:1024-8.
66. Salazar H, Raggi P. Usefulness of electron-beam computed tomography. Am J Cardiol 2002;89:17B-22B.
67. Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004;19:1489-96.
68. Sharples E, Pereira D, Summers S etal. Coronary artery calcification measured with electron-beam computerized tomography correlates poorly with coronary artery angiography in dialysis patients. Am J Kidney Dis 2004;43:313-9.
69. Haydar A, Hujairi N, Covic A, Pereira D, Rubens M, Goldsmith D. Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography. Nephrol Dial Transplant 2004;19:2307-12.
70. Moe SN, O'Neill KD, Fineberg N etal. Assessment of vascular calcification in ESRD patients using spiral CT. Nephrol Dial Transplant 2003;18:1152-8.
71. Nitta K, Akiba T, Suzuki K etal. Assessment of coronary artery calcification in hemodialysis patients using multi-detector spiral CT scan. Hypertens Res 2004;27:527-33.
72. Taniwaki H, Ishimura E, Tabata T etal. Aortic calcification in haemodialysis patients with diabetes mellitus. Nephrol Dial Transplant 2005;20:2472-8.
73. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009;Suppl 113:S1-S130.
74. Kauppila LI, Polak JF, Cupples LA, Hannan MT, Kiel DP, Wilson PW. New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-years follow-up study. Atherosclerosis 1997;132:245-50.
75. Ogawa T, Ishida H, Matsuda N etal. Simple evaluation of aortic arch calcification by chest radiography in hemodialysis patients. Hemodial Int 2009;13:301-6.
76. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium×phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant 1999;14:2907-14.
77. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
78. Cozzolino M, Staniforth ME, Liapis H etal. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 2003;64:1653-61.
79. Block GA, Spiegel DM, Ehrlich J etal. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-24.
80. Proudfoot D, Davies JD, Skepper JN, Weissberg PL, Shanahan CM. Acetylated low-density lipoprotein stimulates human vascular smooth muscle cell calcification by promoting osteoblastic differentiation and inhibiting phagocytosis. Circulation 2002;106:3044-50.
81. Qunibi W, Moustafa M, Muenz LR etal. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51:952-65.
82. Brown EM, MacLeod RJ. Extracellular calcium sensing receptors as integrators of multiple metabolic signals. Cell Calcium 2004;35:209-16.
83. Molostvov G, James S, Fletcher S etal. Extracellular calcium-sensing receptor is functionally expressed in human artery. Am J Physiol Renal Physiol 2007;293:F946-55.
84. Alam MU, Kirton JP, Wilkinson FL etal. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res 2009;81:260-8.
85. Ivanovski O, Nikolov IG, Joki N etal. The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE(-/-)) mice. Atherosclerosis 2009;205:55-62.
86. Lopez I, Aguilera-Tejero E, Mendoza FJ etal. Calcimimetics R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 2006;17:795-804.
87. Tamura K, Suzuki Y, Matsushita M etal. Prevention of aortic calcification by etidronate in the renal failure rat model. Eur J Pharmacol 2007;558:159-66.
88. Saito E, Wachi H, Sato F, Sugitani H, Seyama Y. Treatment with vitamin k2 combined with bisphosphonates synergistically inhibits calcification in cultured smooth muscle cells. J Atheroscler Thromb 2007;14:317-24.
89. Hashiba H, Aizawa S, Tamura K, Kogo H. Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects. Ther Apher Dial 2006;10:59-64.
90. Persy V, De Broe M, Ketteler M. Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels? Kidney Int 2006;70:1537-8.